Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Luigi Gargiulo; Luciano Ibba; Piergiorgio Malagoli; Fabrizio Amoruso; Giuseppe Argenziano; Anna Balato; Federico Bardazzi; Martina Burlando; Carlo Giovanni Carrera; Giovanni Damiani; Paolo Dapavo; Valentina Dini; Chiara Franchi; Francesca Maria Gaiani; Giampiero Girolomoni; Claudio Guarneri; Claudia Lasagni; Francesco Loconsole; Angelo Valerio Marzano; Martina Maurelli; Matteo Megna; Diego Orsini; Francesca Sampogna; Massimo Travaglini; Mario Valenti; Antonio Costanzo; Alessandra Narcisi

doi:10.3390/jcm13020495

Key Points

To assess the three-year real-world effectiveness, tolerability, and treatment retention of risankizumab in individuals with psoriasis, including those with disease in difficult-to-treat sites.
Three-year retrospective multicenter study conducted in routine clinical practice settings across dermatology centers (IL PSO).
Monitored patients receiving risankizumab for clinical effectiveness, adverse events, and drug survival, with specific evaluation of difficult-to-treat anatomical regions.
Risankizumab sustained therapeutic effectiveness over the three-year real-world observation period.
Treatment demonstrated favorable tolerability and safety alongside high drug survival rates, including in patients presenting with difficult-to-treat disease.

Implication

Retrospective multicenter cohort study demonstrates long-term effectiveness and safety of risankizumab in psoriasis, highlighting durable control across difficult-to-treat areas.

Abstract

This study supports the long-term effectiveness and safety of risankizumab in a real-world setting, even in patients involving difficult-to-treat areas.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gargiulo et al. (2024) studied this question.

synapsesocial.com/papers/69d77ba1f44a16d01ef31542 https://doi.org/10.3390/jcm13020495

View Full Paper

Ask AI

Bookmark

Share

Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Key Points

Implication

Abstract

Discussion

Cite This Study

Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading